Home Featured

Featured

Random

The Role of Oxytocin in MDMA’s Prosocial Effects

Psychedelic Bulletin: Microdosing Study Causes a Stir; COMPASS Secures 5th US Patent; Leave Toads Alone?

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

PT267 – Rebecca Kronman, LCSW – Psychedelics, Pregnancy, and Parenthood

MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing

Psychedelic Bulletin: atai IPOs on Nasdaq; Cybin to Target Anxiety Indications;...

The World Boxing Council and Wesana Health Announce Multi-Year Joint Efforts...

Psychedelic Research Bulletin: July & August 2021

Entheon Biomedical Corp. Announces Agreement to Acquire Lobo Genetics Inc.

How Psychedelics Can Treat Eating Disorders

PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke

COMPASS Pathways joins forces with King’s College London and South London...

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in...

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and...

Biotech Veteran David Kideckel Joins the Board of PharmaDrug

12 3...100 Page 1 of 100

EDITOR PICKS

Psychedelic Bulletin: Microdosing Study Causes a Stir; COMPASS Secures 5th US...

Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Numinus Announces Departure of Stacey Wallin

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

PTSF49 – MDMA For Alcoholism, The Placebo Effect, and Ceremonial Magicians

Psychedelic Bulletin: Field Trip Raising $83m; NYU Langone Launches Psychedelic Medicine...

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.